[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601507":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":58,"collaborators":60,"id":64,"slug":26,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":26,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Home-Based Intermittent Light Therapy","EXPERIMENTAL","Adults with a major depressive episode (MDE) randomized to receive active home-based 60Hz intermittent light therapy, delivered five days per week for three weeks for a total of 15x30-minute daily sessions.",[13],"Device: 60Hz Intermittent Light Therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham Home-Based Light Therapy","SHAM_COMPARATOR","Adults with a major depressive episode (MDE) randomized to receive sham home-based light therapy, delivered five days per week for three weeks for a total of 15x30-minute daily sessions.",[19],"Device: Sham Light Therapy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","60Hz Intermittent Light Therapy","Intermittent 60 Hz flickering white light delivered via a wearable headset.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Sham Light Therapy","Constant white light delivered via a wearable headset.",[15],[32],{"name":33,"affiliation":5,"role":34},"Giuseppina Pilloni, PhD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Shayna Pehel","CONTACT","929-455-5104","Shayna.Pehel@nyulangone.org",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Giuseppina Pilloni","929-455-5317","Giuseppina.Pilloni@nyulangone.org",[46],{"facility":5,"status":47,"city":48,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":26},"RECRUITING","New York","10017","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-74.00597,40.71427,{"lat":56,"lon":55},{"type":59,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[61],{"name":62,"class":63},"Syntropic Medical","UNKNOWN","100601507",false,"NCT07111390","Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)","A Feasibility Pilot Study of Home-Based Intermittent 60Hz Light Therapy for the Treatment of Depression","Inclusion Criteria:\n\n* Age between 24 and 65 years (inclusive)\\*.\n* Confirmed diagnosis of Major Depressive Disorder (MDD), based on MINI interview.\n* Hamilton Depression Rating Scale (HDRS-17) score ≥17 at screening.\n* On a stable dose of antidepressant medication for at least 30 days prior to HDRS-17 screening.\n* No evidence of premorbid cognitive impairment, as demonstrated by a standard score \\>85 on the WRAT-5 Reading Recognition Subtest.\n* Confirmed access to a local provider that has primary responsibility for the subjects' clinical care, and who is available for contact in case of increased subject risk due to depressive symptoms.\n* Able to provide informed consent and comply with study procedures.\n* Access to a quiet space suitable for home-based light stimulation sessions.\n* English speaking: All study materials and assessments are only validated in English\n\nExclusion Criteria:\n\n* Presence of primary neurological or autoimmune disorders.\n* Presence of psychiatric comorbidities as determined by the MINI interview (e.g., anxiety disorders, OCD, PTSD, bipolar disorder, psychotic disorder).\n* Current or recent diagnosis of alcohol or substance use disorder.\n* History of bipolar disorder or any psychotic disorder.\n* Clinically significant suicidal ideation or behavior, based on clinician judgment and the Columbia-Suicide Severity Rating Scale (C-SSRS).\n* History of seizure disorder or epilepsy.\n* History of migraine, tinnitus, or photosensitivity.\n* Diagnosis of retinal disease, cataract, or other visual impairments that may interfere with light exposure.\n* Regular use of anti-inflammatory drugs or anticoagulants (e.g., clopidogrel).\n* Pregnancy and Breastfeeding: Currently pregnant, planning pregnancy during the study period, or breastfeeding","ALL","24 Years","65 Years",{"count":74,"type":75},40,"ESTIMATED","INTERVENTIONAL",[78],"NA","This pilot study evaluates the feasibility, safety, and preliminary efficacy of home-based 60Hz intermittent light therapy in adults with a major depressive episode (MDE). Participants will be randomized in a 2:1 ratio to receive either active or sham 60Hz intermittent light stimulation for 30 minutes daily (Monday through Friday) over three weeks. The light is delivered through a wearable headset. Clinical assessments will be conducted remotely at baseline, mid-point, post-treatment, and follow-up to measure changes in depressive symptoms.",[81,82,83,84],"Depression","MDD","Major Depressive Disorder","Major Depressive Episode",[86,82,81,87,88,89,90],"Brain stimulation","Light therapy","Wearable","Neuromodulation","Telehealth","2026-06-25",{"date":93,"type":94},"2026-06-29","ACTUAL",{"date":96,"type":94},"2025-08-18",{"date":98,"type":75},"2027-02-01",{"name":5,"class":6},1]